Health Through Evidence
@EvidenceThrough
Experts in Health Economics, Access, and Value Consulting #Health_economics #HEOR #HTA
You might like
The Health Through Evidence team wishes you a Merry Christmas and a Happy New Year! ✨
Last week, our team had the privilege of participating in the @ISPORorg Europe 2025 Congress in Glasgow, #Scotland. HTE proudly presented six posters, showcasing our expanding work across #RWE, #HEOR, and the role of #AI in HE. Visit our posters at hte.gr/health-through…
As part of the panel discussion “Real-World Impact – Mechanisms to Support HTA and Contain Access Inequalities” at the 10th Annual Health Technology Assessment Conference. healthdaily.gr/2025/09/30/g-g…
HTE had the pleasure of participating in and supporting the 10th HTA #conference 2025, themed “#HTA in Transition: Delivering #Value Through Inclusive Health Policies”, organized by #Health Daily and BOUSSIAS, held on September 30th in Athens, Greece. healthdaily.gr/2025/09/30/g-g…
We’re happy to share that our latest study has been published in the open-access journal Medical Sciences. 📝 Title: Disease #Burden and #Unmet #Medical Needs in Patients with #Ulcerative Colitis in Greece: A Cross-Sectional #patient #Survey. mdpi.com/2076-3271/13/3…
We’re happy to share our study: “#Burden of respiratory syncytial virus disease in infants and the potential value of maternal #Immunization in Greece,” published in open access journal Frontiers in Public #Health. @FrontPubHealth 🔗 Read more: frontiersin.org/journals/publi…
🌞 The Health Through Evidence team wishes you a Happy Summer! 🌴 As the #summer break begins, we’re taking a moment to step back, relax, and recharge. Wishing our colleagues, #partners, and #friends a joyful and restful holiday season.💙 #HTE #HealthThroughEvidence #SummerBreak
Publication Alert! We’re excited to share our latest publication: #Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine to prevent pneumococcal disease in the Greek pediatric population published in Expert Review of Vaccines. Read here: tandfonline.com/doi/10.1080/14…
Today, May 19th, we observe World Inflammatory Bowel Disease (IBD) Day, a day to raise #awareness and understanding of a chronic condition that affects millions around the globe. 📝 Explore the full insights from recent studies: 🔗 lnkd.in/dn3MVMyB #IBDawareness
🌼 Happy #Easter from all of us at HTE – Health Through Evidence!🐣 As we #celebrate this season of renewal, we’re grateful for our colleagues, partners, and #friends . 🌸 May your Easter be filled with peace, joy, and a little bit of chocolate! 🍫💜 #EasterWishes #HappyEaster
We are delighted to share our latest publication: "Does #Real -World Evidence of the #Economic Burden of Lung #Cancer in Greece Exist? A Systematic Review of the Literature" in @CurrentOncology. 📖 Read the full study here: lnkd.in/dyj-kMsx
We’re excited 😀to share our latest publication: “#Cost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Severely Active #Ulcerative #Colitis in Greece” published in Value in Health Regional Issues. @ISPORJournals Find out more at: pubmed.ncbi.nlm.nih.gov/39954537/
We are delighted to share our publication,“Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette–Guerin in patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from six 🏥 in🇬🇷 @CurrentOncology
Delighted to have been part of @ISPORorg conference in Barcelona, Spain! Our team proudly presented 15 research posters at #ISPOR Europe 2024, across diverse diseases. A special moment was having 3 posters rank in the top 5% 🏆 See more at our website:lnkd.in/dgw-i9mt.
We are excited 😃 to announce that HTE will be participating in the upcoming @ISPORorg conference. Our team will be presenting 15 posters covering a diverse range of diseases. We are deeply honored that 3 of our posters have been recognized as #Top 5% Finalists.
Find out more at:mdpi.com/2076-393X/12/1… @Vaccines_MDPI
#Publication Alert: #Happy to share our most recent, #open-access publication ”#Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for #Prevention of Respiratory Syncytial Virus Among Older Adults in #Greece ” in @Vaccines_MDPI @MDPIOpenAccess
Happy Easter from Health Through Evidence! 🐣🐰🌷 Wishing all our #partners, #colleagues and hashtag#friends a very Happy Easter! #HappyEaster #Easter #Happy #2024
Health Through Evidence had the pleasure of sponsoring the ‘9th Annual #HTA Conference’ which was held on April 23rd in Athens. Once again, it was an excellent #HTA conference! Learn more at :hte.gr/hta-conference/ #HTA #HTAConference #HealthTechnologyAssessment #HTA24gr
Happy share that our cross-sectional #study “Patients’ disease burden, satisfaction, and use of technology in rheumatoid arthritis (RA) in #Greece” was presented last week, at the PanHellenic Conference on Health Economics & Policies 2023. Find out more at:lnkd.in/dV_A4c-F
Happy to share our latest #publication "Lorlatinib as a first-line #treatment of adult #patients with anaplastic lymphoma kinase-positive advanced non-small cell #lung #cancer:Α #cost-effectiveness analysis in #Greece" in the Expert Review of pharmacoeconomics & Outcomes Research
United States Trends
- 1. #OlandriaxRahulMishra N/A
- 2. Homan N/A
- 3. Kanye N/A
- 4. Roval N/A
- 5. #MondayMotivation N/A
- 6. Ran Gvili N/A
- 7. Michael Burry N/A
- 8. Amex N/A
- 9. $GME N/A
- 10. #MaduroCiliaHeroes N/A
- 11. $SLV N/A
- 12. Medic N/A
- 13. Chris Madel N/A
- 14. Signal N/A
- 15. JUST ANNOUNCED N/A
- 16. #MondayMorning N/A
- 17. Scheelhaase N/A
- 18. Paul Newman N/A
- 19. Cramer N/A
- 20. Maia 200 N/A
Something went wrong.
Something went wrong.